Similarly, using neoantigen data reported by Charoentong et al. [34], the median number of predicted neoantigens in TCGA BRCA1- and BRCA2-deficient breast cancers were found to be 2.0 and 2.3 fold higher, respectively, compared to BRCA-proficient breast cancers (P = 2.0 x 10−6 and 2.0 x 10−4, respectively). This evidence concerns the gene BRCA1 and breast carcinoma.